COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN

被引：0
|
作者：
Taxonera, C. [1 ]
de Andres-Nogales, F. [2 ]
Garcia, S. [3 ]
Sanchez-Guerrero, A. [4 ]
Menchen, B. [4 ]
Peral, C. [5 ]
Cabez, A. [5 ]
Gomez, S. [5 ]
Lopez, A. [6 ]
Casado, M. A. [2 ]
Menchen, L. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] PORIB, Pozuelo De Alarcon M, Spain
[3] Hosp Univ Miguel Servet, Zaragoza, Spain
[4] Hosp Univ Puerta de Hierro Majadahonda, Madrid, Spain
[5] Pfizer SLU, Madrid, Spain
[6] Pfizer SLU, Madrid M, Spain
[7] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI17
引用
收藏
页码：S619 / S619
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN
    Menchen, L.
    de Andres-Nogales, F.
    Garcia, S.
    Sanchez-Guerrero, A.
    Menchen, B.
    Cabez, A.
    Gomez, S.
    Lopez, A.
    Casado, M. A.
    Peral, C.
    Taxonera, C.
    VALUE IN HEALTH, 2019, 22 : S619 - S619
  • [2] Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
    Wu, Bin
    Wang, Zhenhua
    Zhang, Qiang
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2291 - 2302
  • [3] Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
    Taxonera, Carlos
    de Andres-Nogales, Fernando
    Garcia-Lopez, Santiago
    Sanchez-Guerrero, Amelia
    Menchen, Belen
    Peral, Carmen
    Cabez, Ana
    Gomez, Susana
    Lopez-Ibanez de Aldecoa, Alejandra
    Casado, Miguel Angel
    Menchen, Luis
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 73 - 83
  • [4] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND
    Sruamsiri, R.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [5] Cost-Effectiveness of Infliximab Scheduled Maintenance Treatment for the Management of Patients With Moderate-to-Severe Ulcerative Colitis
    Monfared, Amir A. Tahami
    Feagan, Brian G.
    GASTROENTEROLOGY, 2013, 144 (05) : S637 - S637
  • [6] COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Beilman, Candace L.
    Fedorak, Richard N.
    Halloran, Brendan P.
    GASTROENTEROLOGY, 2019, 156 (06) : S260 - S261
  • [7] Cost-effectiveness of immunomodulators versus infliximab for adults with moderate-to-severe ulcerative colitis.
    Malone, D.
    Hurwitz, J.
    Lofland, J.
    Nejadnik, B.
    Vanderpoel, J.
    Waters, H.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S53 - S54
  • [8] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [9] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [10] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIA
    Hansen, Tawnya
    Mak, Joyce
    Underwood, Fox
    Windsor, Joseph
    King, James
    Quan, Joshua
    Buie, Michael
    Coward, Stephanie
    Frolkis, Alex
    Leung, Alexander
    Ma, Christopher
    Novak, Kerri
    Panaccione, Remo
    Qian, Yiming
    Burisch, Johan
    Gearry, Richard
    Ng, Siew
    Kaplan, Gilaad
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S44 - S44
12345